Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $137.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

bio-rad laboratories -cl b (BIO/B) Snapshot

Open
$137.00
Previous Close
$137.00
Day High
$137.00
Day Low
$137.00
52 Week High
04/6/15 - $137.93
52 Week Low
10/13/14 - $108.79
Market Cap
3.9B
Average Volume 10 Days
54.3
EPS TTM
$3.73
Shares Outstanding
5.1M
EX-Date
--
P/E TM
36.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIO-RAD LABORATORIES -CL B (BIO/B)

Related News

No related news articles were found.

bio-rad laboratories -cl b (BIO/B) Related Businessweek News

View More BusinessWeek News

bio-rad laboratories -cl b (BIO/B) Details

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products include reagents, instruments, and software, which address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force and a service network. It has operations in Europe, Pacific Rim, the United States, and internationally. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

7,600 Employees
Last Reported Date: 03/2/15
Founded in 1952

bio-rad laboratories -cl b (BIO/B) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $843.1K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $423.3K
Chief Operating Officer
Total Annual Compensation: $609.0K
Executive Vice President and President of Cli...
Total Annual Compensation: $432.6K
Chief Strategy Officer
Total Annual Compensation: $425.7K
Compensation as of Fiscal Year 2014.

bio-rad laboratories -cl b (BIO/B) Key Developments

Bio-Rad Laboratories, Inc. Announces Launch of Bioplex(R) 2200 25-OH Vitamin D Kit

Bio-Rad Laboratories, Inc. announced the launch of the BioPlex(r) 2200 25-OH Vitamin D kit for use on the company's BioPlex(r) 2200 system in U.S. markets. The assay offers a fully-automated method for the quantitative measurement of total 25-hydroxyvitamin D in human serum. The Vitamin D testing market has seen considerable growth over the past several years. In addition to the critical role Vitamin D plays in bone health, a number of recent studies have demonstrated associations between Vitamin D deficiency and an increased risk of cardiovascular disease, autoimmune disease, and cancer. Based on data from a National Health and Nutrition Examination Survey several years ago, the CDC estimates that approximately 30% of the U.S. population has low levels of Vitamin D. The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system, providing clinical laboratories the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, helps consolidate workstations, and simplifies workflow.

Bio-Rad Laboratories, Inc. Provides Earnings Guidance for the Year 2015

Bio-Rad Laboratories, Inc. provided earnings guidance for the year 2015. Looking to 2015, the company estimates that CapEx spending will be in the $130 million to $140 million range, as it continue to invest in its global ERP system and facilities. The combined result of opportunities and challenges leads the company to the expectation of sales growth in 2015 similar to 2014. That is, around 3% on a currency-neutral basis for the full year. The combined result of opportunities and challenges leads to the expectation of sales growth in 2015 similar to 2014. That is, around 3% on a currency-neutral basis for the full year. In sum, consolidated currency-neutral outlook for full year gross margin is to be around 55% despite price pressure across several product lines and regions, and outlook for the currency-neutral operating margin is to be around 9% for the full year.

Bio-Rad Laboratories, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014

Bio-Rad Laboratories, Inc. announced unaudited consolidated earnings results for the fourth quarter and fiscal year ended December 31, 2014. For the quarter, the company reported revenues were $598.2 million, a decrease of 0.7% compared to $602.6 million reported for the fourth quarter of 2013. On a currency-neutral basis, quarterly revenues increased 4.6% compared to the same period in 2013. Fourth-quarter gross margin was 53.1% compared to 53.6% during the same quarter in 2013. Net income for the fourth quarter of 2014 was $39.0 million, or $1.34 per share on a fully diluted basis, compared to $30.1 million, or $1.04 per share during the same period in 2013. The effective tax rate for the fourth quarter of 2014 of 14.7% was significantly lower than the effective tax rate for the fourth quarter of 2013 of 32.3% mainly due to the reinstatement of the 2014 U.S. research & development tax credit and releases of valuation allowances and tax reserves. Income from operations was $50,586,000 compared to $52,317,000 a year ago. Income before income taxes was $45,746,000 compared to $44,510,000 a year ago. For the full year of 2014, sales were $2,175.0 million compared to $2,132.7 million in 2013, an increase of 2.0%, or 3.3% on a currency neutral basis. Full-year gross margin was 54.2% compared to 55.3% reported in 2013. The net decline in gross margin is largely attributable to $11.6 million resulting from plant closures and product line discontinuations. Full-year net income in 2014 was $88.8 million, or $3.05 per share on a fully diluted basis, compared to $77.8 million, or $2.69 per share in 2013. The change in net income was primarily due to a reduction of $18.7 million of annual interest expense in 2014 arising from the redemption of Senior Subordinated Notes in September 2013 and $15.0 million less in settlement costs associated with the FCPA matter. Income from operations was $149,984,000 compared to $169,456,000 a year ago. Income before income taxes was $131,557,000 compared to $112,385,000 a year ago. Net cash provided by operating activities was $273,312,000 compared to $169,136,000 a year ago. Payments for acquisitions and long-term investments were $44,627,000 compared to $72,054,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO/B:US $137.00 USD 0.00

BIO/B Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $48.87 USD -1.10
BioMerieux €98.29 EUR +0.23
DiaSorin SpA €41.18 EUR +0.09
PerkinElmer Inc $51.44 USD -0.21
Siemens Ltd 1,265 INR +36.80
View Industry Companies
 

Industry Analysis

BIO/B

Industry Average

Valuation BIO/B Industry Range
Price/Earnings 45.1x
Price/Sales 1.8x
Price/Book 1.8x
Price/Cash Flow 37.1x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-RAD LABORATORIES -CL B, please visit www.bio-rad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.